ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: MannKind Corporation (MNKD) Report Updated: Mar 18, 2017 | Print This Page

Get more stock ratings by Louis Navellier

MannKind Corporation (MNKD)

Rating: Strong Sell Volatility: Aggressive
Total Grade: F Industry: Biotechnology
Competitors: ARRY,CLVS,CLCD,GLPG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
March April May June July August September October November December January February

Rating: Weekly View

This Week: F down downgrade
Last Week: D same upgrade
Two Weeks Ago: N up no change
service keys

MannKind Corporation© quotemedia

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.